X4 Pharmaceuticals Inc.

06/11/2025 | Press release | Distributed by Public on 06/11/2025 14:17

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 9, 2025, X4 Pharmaceuticals Inc. (the "Company") held its annual meeting of stockholders (the "Annual Meeting"), at which a quorum was present. The final results for each of the proposals submitted to a vote of the Company's stockholders at the Annual Meeting are set forth below. These proposals are described in detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 25, 2025. As of April 15, 2025, the record date for the Annual Meeting, there were 173,662,376 shares of common stock, par value $0.001 per share, outstanding and entitled to vote. All votes and corresponding numbers in this Current Report on Form 8-K are represented on a pre-reverse stock split basis as of the April 15, 2025 record date of the Annual Meeting, which preceded the April 28, 2025 effective date of the Company's 1-for-30 reverse stock split.
Proposal 1 - Election of Directors
The Company's stockholders elected the person listed below as director, to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successor is duly elected and qualified or until their earlier death, resignation of removal. The votes cast were as follows:
Nominees
For
Withheld
Broker Non-Votes
R. Keith Woods 52,191,014 29,872,082 53,811,292
Proposal 2 - Ratification of the Selection of Independent Registered Public Accounting Firm
The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP by the Audit Committee of the Board of Directors as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. The votes cast were as follows:
For
Against
Abstain
Broker Non-Votes
128,889,553 6,595,740 389,095 -
Proposal 3 - Non-Binding Advisory "Say-On-Pay" Vote on Named Executive Officer Compensation
The Company's stockholders approved, by a non-binding "say-on-pay" vote, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement relating to the Annual Meeting. The votes cast were as follows:
For
Against
Abstain
Broker Non-Votes
67,793,970 12,234,847 2,034,279 53,811,292
X4 Pharmaceuticals Inc. published this content on June 11, 2025, and is solely responsible for the information contained herein. Distributed via Edgar on June 11, 2025 at 20:17 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]